Trevena, Inc.
1018 West 8th Avenue
Suite A
King of Prussia
Pennsylvania
19406
United States
Tel: 610-354-8840
Website: http://www.trevenainc.com/
Email: IR@trevenainc.com
259 articles with Trevena, Inc.
-
Trevena Reports Second Quarter 2022 Results and Provides Business Update
8/11/2022
Trevena, Inc. today reported its financial results for the second quarter ended June 30, 2022 and provided an overview of its recent operational highlights.
-
Trevena to Release Second Quarter 2022 Financial Results on August 11, 2022 Company to host a Conference Call & Webcast at 8:00 a.m. ET
8/8/2022
Trevena, Inc. today announced that it will release its financial results for the second quarter ended June 30, 2022, prior to the market open on Thursday, August 11, 2022.
-
Trevena, Inc. Announces Registered Direct Offering of Preferred Stock
7/29/2022
Trevena, Inc. (Nasdaq: TRVN) ("Trevena" or the "Company"), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor for the purchase and sale of 1,800 shares of Series A convertible preferred stock.
-
Trevena, Inc. Announces Closing of Registered Direct Offering of Preferred Stock - July 29, 2022
7/29/2022
Trevena, Inc. announced the closing of its previously announced registered direct offering with a single healthcare-focused institutional investor for the purchase and sale of 1,800 shares of Series A convertible preferred stock and 200 shares of Series B convertible preferred stock and warrants exercisable to purchase up to an aggregate of 8,000,000 shares of common stock.
-
Trevena Announces Positive Topline OLINVYK Cognitive Function Data and Provides General Business Update
7/28/2022
Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, reported positive topline results from its post-approval study designed to assess the impact on cognitive function in subjects treated with OLINVYK compared to IV morphine.
-
Trevena Announces the Publication of an Expert Review on the Clinical Profile of OLINVYK® in Post-Operative Care
6/14/2022
Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a publication in Expert Review of Neurotherapeutics titled “ A critical review of oliceridine injection as an IV opioid analgesic for the management of severe acute pain” by Eugene R. Viscusi, M.D.
-
Trevena to Participate at the JMP Securities Life Sciences Conference
6/10/2022
Trevena, Inc. announced that Carrie Bourdow, President & CEO, and Mark Demitrack, M.D., Senior Vice President and Chief Medical Officer, will participate in a fireside chat at the JMP Securities Life Sciences Conference being held in New York on June 15 - 16, 2022.
-
Trevena to Present at the H.C. Wainwright Global Investment Conference
5/18/2022
Trevena, Inc. announced that Carrie Bourdow, President & CEO and Barry Shin, CFO, will be participating in the H.C. Wainwright Global Investment Conference being held May 23 - 26, 2022.
-
Trevena Reports First Quarter 2022 Results and Provides Business Update
5/11/2022
Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the first quarter ended March 31, 2022 and provided an overview of its recent operational highlights.
-
Trevena to Release First Quarter 2022 Financial Results on May 11, 2022
5/9/2022
Trevena, Inc. announced that it will release its financial results for the first quarter ended March 31, 2022, prior to the market open on Wednesday, May 11, 2022.
-
It was yet another busy week for clinical trial news, with a range of studies for COVID-19, various cancers, fungal infections and other indications.
-
Trevena Announces Results from Respiratory Physiology Study of Head-to-Head Comparison of OLINVYK® and IV Morphine in Elderly/Overweight Subjects
4/20/2022
Trevena, Inc. today announced results from its double blinded, crossover study evaluating OLINVYK® (oliceridine) injection for the management of acute pain, in elderly/overweight.
-
The major money winners this week included a DNA editing platform, a machine-learning platform that creates digital patient “twins” and wearable temperature-monitoring patches.
-
Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with R-Bridge Healthcare Fund
4/18/2022
Trevena, Inc. announced receipt of the first $15 million tranche from its royalty-based financing agreement with an affiliate of R-Bridge Healthcare Fund.
-
OLINVYK® data selected as President’s Choice abstract at Annual Regional Anesthesiology and Acute Pain Medicine Meeting and Featured at American Burn Association Annual Meeting
4/13/2022
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a summary of activities at recent medical meetings, relating to OLINVYK® (oliceridine) injection, in several core therapeutic areas.
-
Trevena Reports Fourth Quarter and Full Year 2021 Results
3/31/2022
Trevena, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2021, and provided an overview of its 2021 and 2022 year-to-date operational highlights.
-
Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare Fund, an affiliate of CBC Group
3/31/2022
Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced that the Company entered into a royalty-based financing with an affiliate of R-Bridge Healthcare Fund.
-
Trevena to Release Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022
3/30/2022
Trevena, Inc. today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2021, prior to the market open on Thursday, March 31st, 2022.
-
Trevena to Present at the 2022 BIO CEO & Investor Conference
2/3/2022
Trevena, Inc. announced that Carrie Bourdow, President & CEO, will present a corporate overview at the BIO CEO & Investor Conference being held from February 14th - 17th, 2022.
-
Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical
1/27/2022
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that China’s National Medical Products Administration (NMPA) has accepted submission of a New Drug Application (NDA) for oliceridine injection